TOKYO, April 2, 2025

东京，2025年4月2日

- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Japanese Foundation for Cancer Research (Chairman:  Toshio Asano, Ph.D., “JFCR”) today announced they have entered into a strategic collaboration to accelerate translational and clinical oncology research.

- 安斯泰来制药公司（东京证券交易所代码：4503，总裁兼首席执行官：冈村直树，“安斯泰来”）和日本癌症研究基金会（主席：浅野俊夫博士，“JFCR”）今天宣布，他们已达成一项战略合作伙伴关系，以加速转化和临床肿瘤学研究。

The collaboration leverages Astellas’ unique scientific, translational and clinical expertise and JFCR’s strength as a world-class comprehensive cancer research center to quickly advance the development of novel treatments for patients with cancers that are resistant to current therapies.

该合作利用了安斯泰来独特的科学、转化和临床专业知识，以及JFCR作为世界级综合癌症研究中心的优势，以快速推进针对当前疗法耐药的癌症患者的新治疗方法的开发。

Under the agreement, projects will be selected jointly based on shared interest and expertise. Selected projects will generate new translational and clinical data for Astellas’ early-stage pipeline assets, which will be integrated with Astellas’ own data to accelerate and refine these programs.

根据协议，将基于共同的兴趣和专业知识共同选择项目。选定的项目将为安斯泰来早期阶段的管线资产生成新的转化和临床数据，这些数据将与安斯泰来自己的数据整合，以加速和优化这些项目。

Through this collaboration, Astellas is committed to strengthening translational science and clinical research in order to deliver innovative new medicines. For JFCR, the collaboration provides early access to Astellas’ pipeline, along with additional resources and expertise to bring these therapies to patients..

通过此次合作，安斯泰来承诺加强转化科学和临床研究，以提供创新的新药。对于日法癌症研究中心而言，此次合作提供了对安斯泰来研发管线的早期访问，以及将这些疗法带给患者的额外资源和专业知识。

Tadaaki Taniguchi, M.D., Ph.D., Chief Research and Development Officer, Astellas

谷口忠明，医学博士，哲学博士，安斯泰来首席研发官

“Collaborations with leading academic centers are at the heart of Astellas’ strategy to deliver valuable medicines through scientific innovation. We are pleased to collaborate with JFCR, one of the largest and well-known cancer centers in Japan, to help advance our oncology pipeline. With a diverse set of early-stage oncology assets spanning multiple cutting-edge modalities, we are committed to delivering the next generation of therapies with outcomes that matter for patients.

“与领先的学术中心合作是安斯泰来通过科学创新提供有价值药物的战略核心。我们很高兴能与日本最大且最知名的癌症中心之一——日本癌症研究基金会（JFCR）合作，以推动我们的肿瘤学管线发展。凭借涵盖多种前沿模式的多样化早期肿瘤学资产，我们致力于提供对患者有实际意义的下一代疗法。

Through our partnerships, we can collectively enhance the insights and expertise that are critical for accelerating the development of new and innovative treatments for patients in need.”.

通过我们的合作伙伴关系，我们能够共同提升对加速为有需要的患者开发新疗法至关重要的洞察力和专业知识。”

Toshio Asano, Ph.D., Chairman, Japanese Foundation for Cancer Research

浅野俊夫博士，日本癌症研究基金会主席

“Bringing new treatments to patients is our mission, and we believe that partnership between industry and academia is essential to drive drug development. We are very pleased to partner with Astellas, which has an innovative pipeline, to accelerate translational research and development. Astellas, with its outstanding global pharmaceutical R&D capabilities, and JFCR, with its unique organization that integrates the hospital and research divisions to enhance drug discovery, will work together to fulfill our mission of “Achieving Better Cancer Control” and “Well-being of People Everywhere”.

“为患者带来新的治疗方法是我们的使命，我们相信产业界与学术界之间的合作对于推动药物开发至关重要。我们非常高兴能与拥有创新研发管线的安斯泰来合作，以加速转化研究与开发。安斯泰来凭借其卓越的全球制药研发能力，以及日本癌症研究基金会（JFCR）凭借其整合医院和研究部门的独特组织结构以促进药物发现，双方将共同努力实现我们‘更好地控制癌症’和‘造福全人类福祉’的使命。”

About Astellas

关于安斯泰来

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need.

安斯泰来是一家全球生命科学公司，致力于将创新科学转化为对患者的 VALUE。我们在肿瘤学、眼科、泌尿科、免疫学和女性健康等疾病领域提供变革性疗法。通过我们的研发项目，我们正在为那些具有高度未满足医疗需求的疾病开创全新的医疗解决方案。

Learn more at .

了解更多，请访问。

www.astellas.com

www.astellas.com

.

。

About Japanese Foundation for Cancer Research (JFCR)

关于日本癌症研究基金会 (JFCR)

The basic principle of JFCR is “Aiming to Improve the Well-being of People Everywhere by Achieving Better Cancer Control.” We aim to clarify the nature and individuality of cancer, contribute to cancer diagnosis, treatment, and prevention, and pioneer the frontiers of life science. To achieve this, we are actively promoting clinical trials for the development of new drugs, clinical research, and translational research that will lead to the development of new treatment and diagnostic methods, and are working to provide advanced cancer treatment to patients.

JFCR的基本原则是“通过实现更好的癌症控制来提高世界各地人民的福祉”。我们旨在阐明癌症的本质和个体差异，为癌症的诊断、治疗和预防做出贡献，并开拓生命科学的前沿。为此，我们正在积极推动新药开发的临床试验、临床研究以及将有助于开发新治疗方法和诊断技术的转化研究，并努力为患者提供先进的癌症治疗。

Astellas Cautionary Notes

安斯泰来警告通知

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties.

在本新闻稿中，有关当前计划、估计、策略和信念的陈述以及其他非历史事实的陈述是关于安斯泰来未来业绩的前瞻性陈述。这些陈述基于管理层当前的假设和信念，并结合其目前可获得的信息，涉及已知和未知的风险与不确定性。

A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

可能导致实际结果与前瞻性声明中讨论的结果存在重大差异的因素包括但不限于：(i) 与医药市场相关的总体经济状况、法律法规的变化，(ii) 汇率波动，(iii) 新产品上市的延迟，(iv) 安斯泰来无法有效营销现有和新产品，(v) 安斯泰来无法在高度竞争的市场中继续有效研发客户认可的产品，以及 (vi) 第三方侵犯安斯泰来的知识产权。

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice..

本新闻稿中包含的关于药品（包括正在开发中的产品）的信息，无意构成广告或医疗建议。

Click below for a copy of the full press release

点击下方获取完整新闻稿的副本